Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $40.78, for a total value of $815,600.00. Following the completion of the transaction, the executive vice president owned 60,000 shares in the company, valued at $2,446,800. The trade was a 25.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Marshall Urist also recently made the following trade(s):

• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Price Performance

RPRX opened at $40.21 on Thursday. The company has a fifty day moving average price of $39.29 and a two-hundred day moving average price of $37.38. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The firm has a market capitalization of $23.21 billion, a PE ratio of 30.46, a P/E/G ratio of 1.93 and a beta of 0.43. Royalty Pharma PLC has a 52 week low of $29.66 and a 52 week high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The business had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. As a group, analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be paid a $0.235 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.3%. Royalty Pharma’s dividend payout ratio (DPR) is currently 66.67%.

Hedge Funds Weigh In On Royalty Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC lifted its holdings in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares in the last quarter. USA Financial Formulas acquired a new stake in Royalty Pharma in the 2nd quarter valued at approximately $32,000. Financial Consulate Inc. acquired a new stake in Royalty Pharma in the 3rd quarter valued at approximately $35,000. Larson Financial Group LLC lifted its stake in Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 306 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its position in Royalty Pharma by 42.1% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 402 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RPRX. TD Cowen boosted their price objective on shares of Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Morgan Stanley reduced their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price objective for the company. Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Finally, Weiss Ratings cut Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Royalty Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $45.60.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.